Claus Scheidereit
- Cancer Research top 0.1%
- NF-κB Signaling Pathways 70
- Immunology top 0.2%
- Immune Response and Inflammation 33
- interferon and immune responses 15
- T-cell and Retrovirus Studies 8
- Molecular Biology top 0.5%
- Cell death mechanisms and regulation 11
- Natural product bioactivities and synthesis 8
- RNA Research and Splicing 8
- Oncology top 0.5%
- Cytokine Signaling Pathways and Interactions 15
- Co-authors
- Daniel KrappmannM. HinzMiguel BeatoMichael NaumannF. Gregory WulczynRobert G. RoederBernd DörkenEunice N. Hatada
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Claus Scheidereit
103 papers receiving 14.0k citations
Hit Papers
Peers
Comparison fields: 5 of 133
- Cancer Research 5.4k
- Immunology 5.3k
- Molecular Biology 7.6k
- Oncology 2.9k
- Pathology and Forensic Medicine 1.2k
Countries citing papers authored by Claus Scheidereit
This map shows the geographic impact of Claus Scheidereit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Scheidereit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Scheidereit more than expected).
Fields of papers citing papers by Claus Scheidereit
This network shows the impact of papers produced by Claus Scheidereit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Scheidereit. The network helps show where Claus Scheidereit may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Claus Scheidereit, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 5 | |
| 2 | 2023 | 3 | |
| 3 | 2022 | 25 | |
| 4 | 2021 | 11 | |
| 5 | 2021 | 51 | |
| 6 | 2020 | 8 | |
| 7 | 2009 | 269 | |
| 8 | 2009 | 16 | |
| 9 | 2009 | 190 | |
| 10 | 2004 | 61 | |
| 11 | 2001 | 448 | |
| 12 | 2000 | 16 | |
| 13 | 2000 | 97 | |
| 14 | 1998 | 43 | |
| 15 | 1998 | 142 | |
| 16 | 1997 | 37 | |
| 17 | 1991 | 197 | |
| 18 | 1991 | 7 | |
| 19 | 1989 | 15 | |
| 20 | 1986 | 95 |
About Claus Scheidereit
Claus Scheidereit is a scholar working on Cancer Research, Immunology and Oncology, having authored 103 papers that have together received 14.3k indexed citations. Recurring topics across this work include NF-κB Signaling Pathways (70 papers), Immune Response and Inflammation (33 papers), Cytokine Signaling Pathways and Interactions (15 papers), interferon and immune responses (15 papers), Cell death mechanisms and regulation (11 papers), T-cell and Retrovirus Studies (8 papers), Natural product bioactivities and synthesis (8 papers) and RNA Research and Splicing (8 papers). The work is most often cited by research in Cancer Research (5.4k citations), Immunology (5.3k citations) and Molecular Biology (7.6k citations). Claus Scheidereit has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Daniel Krappmann, M. Hinz, Miguel Beato, Michael Naumann, F. Gregory Wulczyn, Robert G. Roeder, Bernd Dörken, Eunice N. Hatada, H.M. Westphal and Seda Çöl Arslan. Their work appears in journals such as Blood, Molecular and Cellular Biology, The EMBO Journal, Nature and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.